Zidesamtinib shows 94% response rate in TKI-naive advanced ROS1-positive lung cancer
New results from the global Phase I/II ARROS-1 trial indicate clinically meaningful activity with the investigational drug zidesamtinib in patients ...
New results from the global Phase I/II ARROS-1 trial indicate clinically meaningful activity with the investigational drug zidesamtinib in patients ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine